Filtered By:
Condition: Thrombosis
Procedure: Coronary Angioplasty
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 869 results found since Jan 2013.
Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
CONCLUSIONS: Prasugrel dose de-escalation reduced the rate of NACE and bleeding, without increasing the rate of ischemic events in NSTE-ACS patients but not in STEMI patients.PMID:35129316 | DOI:10.4070/kcj.2021.0293
Source: Korean Circulation Journal - February 7, 2022 Category: Cardiology Authors: You-Jeong Ki Bong Ki Lee Kyung Woo Park Jang-Whan Bae Doyeon Hwang Jeehoon Kang Jung-Kyu Han Han-Mo Yang Hyun-Jae Kang Bon-Kwon Koo Dong-Bin Kim In-Ho Chae Keon-Woong Moon Hyun Woong Park Ki-Bum Won Dong Woon Jeon Kyoo-Rok Han Si Wan Choi Jae Kean Ryu Myu Source Type: research
A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial
CONCLUSIONS: Our findings support the use of DAT in the majority of patients. A small subgroup of patients might benefit from TAT and we propose a novel clinical risk score to select these patients.PMID:35105533 | DOI:10.4244/EIJ-D-21-00165
Source: EuroIntervention - February 2, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Bastiaan Zwart Willem Lambertus Bor Anne Johanna Wilhelmina Maria de Veer Bakhtawar Khan Mahmoodi Johannes Christiaan Kelder Gregory Y H Lip Deepak L Bhatt Christopher P Cannon Jurri ën Maria Ten Berg Source Type: research
Clinical Outcomes After Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms
In conclusion, these data demonstrate a higher risk for ischemic events in patients with 2 CYP2C19 LOF alleles who are prescribed clopidogrel, seen at 3 months after PCI, that is not sustained for 12 months.
Source: Journal of Cardiovascular Pharmacology - February 1, 2022 Category: Cardiology Tags: Original Article Source Type: research
Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis
CONCLUSION: Genotype-guided antiplatelet treatment could reduce the risk of MACEs without increasing the risk of bleeding events as compared with the standard treatment in patients with CAD or those undergoing PCI. In addition, Genotype-guided antiplatelet treatment might benefit Chinese population or patients with ACS.PMID:34995471 | DOI:10.18433/jpps32140
Source: J Pharm Pharm Sci - January 7, 2022 Category: Drugs & Pharmacology Authors: Borui Tang Xin Wang Xinrui Wang Lihong Liu Zhuo Ma Source Type: research
Clinical outcomes for intracoronary imaging strategies at different medical facilities in Japanese patients with coronary artery disease: the SAKURA imaging PCI Registry
AbstractThe relationships between intracoronary imaging modalities and outcomes among Japanese patients with coronary artery disease (CAD) based on the type of medical facility providing outpatient care remain unclear. In this multicenter prospective study (SAKURA PCI Registry), we aimed to investigate the clinical outcomes of patients with CAD who underwent percutaneous coronary intervention (PCI) between April 2015 and December 2018. In this registry, we investigated differences in patient characteristics, intracoronary imaging modalities, and clinical outcomes between two types of medical facilities. Of the 414 patients...
Source: Heart and Vessels - January 1, 2022 Category: Cardiology Source Type: research
